Cost-effective osteoporosis treatment thresholds: the United States perspective

被引:349
作者
Tosteson, A. N. A. [1 ,2 ,3 ]
Melton, L. J., III [4 ]
Dawson-Hughes, B. [5 ]
Baim, S. [6 ]
Favus, M. J. [7 ]
Khosla, S. [8 ]
Lindsay, R. L. [9 ]
机构
[1] Dartmouth Med Sch, Clin Res HB7505, Lebanon, NH 03756 USA
[2] Dartmouth Med Sch, Multidisciplinary Clin Res Ctr Musculoskeletal Di, Lebanon, NH USA
[3] Dartmouth Med Sch, Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA
[4] Mayo Clin, Div Epidemiol, Coll Med, Rochester, MN USA
[5] Tufts Univ, Human Nutr Res Ctr Aging, Jean Mayer USDA, Boston, MA 02111 USA
[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[7] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[8] Mayo Clin, Coll Med, Div Endocrinol, Rochester, MN USA
[9] Helen Hayes Hosp, Reg Bone Ctr, W Haverstraw, NY USA
关键词
cost-effectiveness; National Osteoporosis Foundation; osteoporosis; practice guidelines; World Health Organization;
D O I
10.1007/s00198-007-0550-6
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
A United States-specific cost-effectiveness analysis, which incorporated the cost and health consequences of clinical fractures of the hip, spine, forearm, shoulder, rib, pelvis and lower leg, was undertaken to identify the 10-year hip fracture probability required for osteoporosis treatment to be cost-effective for cohorts defined by age, sex, and race/ethnicity. A 3% 10-year risk of hip fracture was generally required for osteoporosis treatment to cost less than $60,000 per QALY gained. Introduction Rapid growth of the elderly United States population will result in so many at risk of osteoporosis that economically efficient approaches to osteoporosis care warrant consideration. Methods A Markov-cohort model of annual United States age-specific incidence of clinical hip, spine, forearm, shoulder, rib, pelvis and lower leg fractures, costs (2005 US dollars), and quality-adjusted life years (QALYs) was used to assess the cost-effectiveness of osteoporosis treatment ($600/yr drug cost for 5 years with 35% fracture reduction) by gender and race/ethnicity groups. To determine the 10-year hip fracture probability at which treatment became cost-effective, average annual age-specific probabilities for all fractures were multiplied by a relative risk (RR) that was systematically varied from 0 to 10 until a cost of $60,000 per QALY gained was observed for treatment relative to no intervention. Results Osteoporosis treatment was cost-effective when the 10-year hip fracture probability reached approximately 3%. Although the RR at which treatment became cost-effective varied markedly between genders and by race/ethnicity, the absolute 10-year hip fracture probability at which intervention became cost-effective was similar across race/ethnicity groups, but tended to be slightly higher for men than for women. Conclusions Application of the WHO risk prediction algorithm to identify individuals with a 3% 10-year hip fracture probability may facilitate efficient osteoporosis treatment.
引用
收藏
页码:437 / 447
页数:11
相关论文
共 38 条
[1]
[Anonymous], BON HLTH OST REP SUR
[2]
Arias Elizabeth, 2003, Natl Vital Stat Rep, V52, P1
[3]
A new look at osteoporosis outcomes: The influence of treatment, compliance, persistence, and adherence [J].
Badamgarav, Enkhe ;
Fitzpatrick, Lorraine A. .
MAYO CLINIC PROCEEDINGS, 2006, 81 (08) :1009-1012
[4]
At what hip fracture risk is it cost-effective to treat?: International intervention thresholds for the treatment of osteoporosis [J].
Borgstroem, F. ;
Johnell, O. ;
Kanis, J. A. ;
Joensson, B. ;
Rehnberg, C. .
OSTEOPOROSIS INTERNATIONAL, 2006, 17 (10) :1459-1471
[5]
Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 [J].
Burge, Russel ;
Dawson-Hughes, Bess ;
Solomon, Daniel H. ;
Wong, John B. ;
King, Alison ;
Tosteson, Anna .
JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 (03) :465-475
[6]
POPULATION-BASED STUDY OF SURVIVAL AFTER OSTEOPOROTIC FRACTURES [J].
COOPER, C ;
ATKINSON, EJ ;
JACOBSEN, SJ ;
OFALLON, WM ;
MELTON, LJ .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1993, 137 (09) :1001-1005
[7]
Meta-analysis of alendronate for the treatment of postmenopausal women [J].
Cranney, A ;
Wells, G ;
Willan, A ;
Griffith, L ;
Zytaruk, N ;
Robinson, V ;
Black, D ;
Adachi, J ;
Shea, B ;
Tugwell, P ;
Guyatt, G .
ENDOCRINE REVIEWS, 2002, 23 (04) :508-516
[8]
Epidemiology and outcomes of osteoporotic fractures [J].
Cummings, SR ;
Melton, LJ .
LANCET, 2002, 359 (9319) :1761-1767
[9]
Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA [J].
Dawson-Hughes, B. ;
Tosteson, A. N. A. ;
Melton, L. J., III ;
Baim, S. ;
Favus, M. J. ;
Khosla, S. ;
Lindsay, R. L. .
OSTEOPOROSIS INTERNATIONAL, 2008, 19 (04) :449-458
[10]
Fisher E S, 1991, Epidemiology, V2, P116, DOI 10.1097/00001648-199103000-00005